46.93
1.79 (3.97%)
| Previous Close | 45.14 |
| Open | 45.14 |
| Volume | 482,438 |
| Avg. Volume (3M) | 490,518 |
| Market Cap | 2,155,694,336 |
| Price / Earnings (TTM) | 109.14 |
| Price / Sales | 1.83 |
| Price / Book | 1.69 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 1.87% |
| Operating Margin (TTM) | -4.31% |
| Diluted EPS (TTM) | 0.460 |
| Quarterly Revenue Growth (YOY) | 9.60% |
| Quarterly Earnings Growth (YOY) | 55.40% |
| Total Debt/Equity (MRQ) | 30.69% |
| Current Ratio (MRQ) | 1.38 |
| Operating Cash Flow (TTM) | 163.69 M |
| Levered Free Cash Flow (TTM) | 122.12 M |
| Return on Assets (TTM) | 0.35% |
| Return on Equity (TTM) | 1.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Omnicell, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 1.78% |
| % Held by Institutions | 104.60% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (Keybanc, 27.85%) | Buy |
| 60.00 (Benchmark, 27.85%) | Buy | |
| Median | 60.00 (27.85%) | |
| Low | 52.00 (Wells Fargo, 10.80%) | Buy |
| Average | 57.33 (22.16%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 48.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Benchmark | 02 Feb 2026 | 60.00 (27.85%) | Buy | 48.70 |
| 09 Dec 2025 | 50.00 (6.54%) | Buy | 43.49 | |
| Keybanc | 08 Jan 2026 | 60.00 (27.85%) | Buy | 50.59 |
| Wells Fargo | 05 Jan 2026 | 52.00 (10.80%) | Buy | 46.93 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2026 | Announcement | Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 |
| 08 Dec 2025 | Announcement | Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management |
| 01 Dec 2025 | Announcement | Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show |
| 20 Nov 2025 | Announcement | Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference |
| 13 Nov 2025 | Announcement | Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |